Evidence map›Paper›PMID 37958555›Full record

ArticleInternational journal of molecular sciences2023

Mitotic Dysregulation at Tumor Initiation Creates a Therapeutic Vulnerability to Combination Anti-Mitotic and Pro-Apoptotic Agents for MYCN-Driven Neuroblastoma.

Lei Zhai, Anushree Balachandran, Rebecca Larkin, Janith A Seneviratne, Sylvia A Chung, Amit Lalwani, Shoma Tsubota, Dominik Beck, Kenji Kadomatsu, Anneleen Beckers and 9 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact, top 69% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 0 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 6 institutions in 3 countries.

Lei ZhaiChildren's Cancer Institute Australia, Lowy Cancer Research Centre, University of New South Wales, Randwick, NSW 2031, Australia.
Anushree BalachandranChildren's Cancer Institute Australia, Lowy Cancer Research Centre, University of New South Wales, Randwick, NSW 2031, Australia.
Rebecca LarkinChildren's Cancer Institute Australia, Lowy Cancer Research Centre, University of New South Wales, Randwick, NSW 2031, Australia.
Janith A SeneviratneChildren's Cancer Institute Australia, Lowy Cancer Research Centre, University of New South Wales, Randwick, NSW 2031, Australia.
Sylvia A ChungAdult Cancer Program, Lowy Cancer Research Centre, University of New South Wales, Sydney, NSW 2031, Australia.
Amit LalwaniChildren's Cancer Institute Australia, Lowy Cancer Research Centre, University of New South Wales, Randwick, NSW 2031, Australia.
Shoma TsubotaDepartment of Biochemistry, Nagoya University Graduate School of Medicine, Nagoya University, Nagoya 466-8550, Japan.ORCID 0000-0001-8609-6784
Dominik BeckSchool of Biomedical Engineering, University of Technology Sydney, Ultimo, NSW 2007, Australia.
Kenji KadomatsuDepartment of Biochemistry, Nagoya University Graduate School of Medicine, Nagoya University, Nagoya 466-8550, Japan.
Anneleen BeckersDepartment of Biomolecular Medicine, Cancer Research Institute Ghent, Ghent University, 9000 Ghent, Belgium.ORCID 0000-0002-6133-5774
Kaat DurinkDepartment of Biomolecular Medicine, Cancer Research Institute Ghent, Ghent University, 9000 Ghent, Belgium.ORCID 0000-0003-1762-5739
Katleen De PreterDepartment of Biomolecular Medicine, Cancer Research Institute Ghent, Ghent University, 9000 Ghent, Belgium.ORCID 0000-0002-7726-5096
Frank SpelemanDepartment of Biomolecular Medicine, Cancer Research Institute Ghent, Ghent University, 9000 Ghent, Belgium.ORCID 0000-0002-6628-8559
Michelle HaberChildren's Cancer Institute Australia, Lowy Cancer Research Centre, University of New South Wales, Randwick, NSW 2031, Australia.
Murray D NorrisChildren's Cancer Institute Australia, Lowy Cancer Research Centre, University of New South Wales, Randwick, NSW 2031, Australia.ORCID 0000-0002-0632-4589
Alexander SwarbrickThe Kinghorn Cancer Centre, Garvan Institute of Medical Research, Darlinghurst, NSW 2010, Australia.
Belamy B CheungChildren's Cancer Institute Australia, Lowy Cancer Research Centre, University of New South Wales, Randwick, NSW 2031, Australia.ORCID 0000-0001-8784-860X
Glenn M MarshallChildren's Cancer Institute Australia, Lowy Cancer Research Centre, University of New South Wales, Randwick, NSW 2031, Australia.
Daniel R CarterChildren's Cancer Institute Australia, Lowy Cancer Research Centre, University of New South Wales, Randwick, NSW 2031, Australia.
UNSW Sydney · AUGhent University · BENagoya University · JPUniversity of Technology Sydney · AUCancer Institute of New South Wales · AUGarvan Institute of Medical Research · AU

Funding

MECHANISMS OF SPEECH MOTOR CONTROLR01DC000594 · NIDCD · HASKINS LABORATORIES, INC. · PI GRACCO, VINCENT L. · 1989 to 2002
$1.2M
NIDCD NIH HHS R01 DC000594
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antimitotic AgentsNeuroblastomaAnimalsCell Line, TumorCell Transformation, NeoplasticGene Expression Regulation, NeoplasticHumansMiceMice, TransgenicN-Myc Proto-Oncogene ProteinAntimitotic AgentsMYCN protein, humanN-Myc Proto-Oncogene Proteincombination therapymitosisMYCNneuroblastomatumorigenesis

Identifiers

PMID37958555
PMCPMC10649872
OpenAlexW4388266044

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.